Profession Notes

You say tomato, but Phyllis Bowen, nutrition and dietetics professor at University of Illinois, Chicago, says possible prostate cancer deterrent and a great source of research funds. Recently added to the list of project directors for the National Foundation for Cancer Research, Bowen and collaborator, Konstantin Christov will use $300,000 in NFCR funding to examine the role of lycopene (a strong antioxidant that gives tomatoes their red color) in apoptosis of prostate cancer cells and hyperplas

Written byBrendan Maher
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
You say tomato, but Phyllis Bowen, nutrition and dietetics professor at University of Illinois, Chicago, says possible prostate cancer deterrent and a great source of research funds. Recently added to the list of project directors for the National Foundation for Cancer Research, Bowen and collaborator, Konstantin Christov will use $300,000 in NFCR funding to examine the role of lycopene (a strong antioxidant that gives tomatoes their red color) in apoptosis of prostate cancer cells and hyperplasia. Earlier clinical studies demonstrated lycopene uptake in the prostates of affected men who ate a regular diet of tomato products prior to surgery. Bowen came across the funding for this ancillary study during the annual retreat of Functional Foods for Health, a joint research program between UI-Chicago and Urbana campuses. A speaker at the retreat, Helmut Sies of Heinrich-Heine-Universitat in Dusseldorf, Germany, suggested that the NFCR be invited. Much of Bowen's research affirms Sies' NFCR-supported findings on lycopene. "I happened to sit with them [the NFCR] one of the days during the retreat and I thought that this was perfect for us," says Bowen who believes that these findings may prove more useful than those from the clinical studies on which they are built. She points out the importance of funding for such add-ons. "Usually the people who do the clinical trials are focused on the task at hand. Costs balloon, and they often don't capture as much data as might be possible."

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies